

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

NCT05040373

Status RECRUITING
Sponsor Alnylam Pharmaceuticals
Enrollment 10 participants

Key Eligibility Criteria

Inclusion (1)

- Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy

Locations (7 total)

Clinical Trial Site, Iowa City, Iowa, United States
Clinical Trial Site, Nantes, France
Clinical Trial Site, Münster, Germany
... and 4 more locations